KEITH WATTS: Open Payments
NPI 1710432190 · MADISON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,845 in 140 payments from 19 companies in 2025. Trend: 2023 $2,945 · 2024 $3,499 · 2025 $2,845
Food & beverage: $2,845
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 21 | $497 |
| ABBVIE INC. | 25 | $444 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $368 |
| Neurocrine BioSciences, Inc. | 11 | $294 |
| Corium, LLC | 11 | $241 |
| Otsuka America Pharmaceutical, Inc. | 7 | $152 |
| Vanda Pharmaceuticals Inc. | 10 | $149 |
| Indivior Inc. | 4 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $105 |
| Janssen Pharmaceuticals, Inc | 5 | $88 |
Products named: ARISTADA, VRAYLAR, CAPLYTA, INGREZZA, Azstarys, REXULTI, FANAPT, SUBLOCADE.
Industry payments across AL — which companies pay providers there.
